B of A Securities Maintains Buy on Insmed, Raises Price Target to $83
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Zemansky maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $62 to $83.
June 28, 2024 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Jason Zemansky maintains a Buy rating on Insmed and raises the price target from $62 to $83.
The Buy rating and increased price target from a reputable analyst at B of A Securities is likely to boost investor confidence in Insmed, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100